Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2025)

Rapid Micro Biosystems' Cash & Equivalents history spans 6 years, with the latest figure at $100000.0 for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 99.55% year-over-year to $100000.0; the TTM value through Sep 2025 reached $100000.0, down 99.55%, while the annual FY2024 figure was $16.9 million, 30.36% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $100000.0 at Rapid Micro Biosystems, down from $200000.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $219.6 million in Q3 2021 and bottomed at $100000.0 in Q1 2023.
  • The 5-year median for Cash & Equivalents is $25.1 million (2022), against an average of $45.3 million.
  • The largest annual shift saw Cash & Equivalents tumbled 99.84% in 2023 before it skyrocketed 22333.0% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $178.4 million in 2021, then plummeted by 84.83% to $27.1 million in 2022, then dropped by 10.27% to $24.3 million in 2023, then tumbled by 30.36% to $16.9 million in 2024, then crashed by 99.41% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Cash & Equivalents are $100000.0 (Q3 2025), $200000.0 (Q2 2025), and $100000.0 (Q1 2025).